1. Introduction {#sec1}
===============

Diabetes mellitus (DM) includes a group of carbohydrate metabolism disorders which is characterized by hyperglycemia and leads to long-term macrovascular and microvascular complications. The prevalence of diabetes mellitus is increasing significantly in most of the developed and many developing countries, and it is of great concern \[[@B1], [@B2]\]. The worldwide prevalence of diabetes mellitus has risen dramatically over the past two decades. It is one of the most common chronic endocrine disorders affecting millions of people worldwide. The International Diabetes Federation (IDF) data indicates that by the year 2025, the number of people affected by diabetes will reach 333 million. Although all forms of diabetes are characterized by hyperglycemia, the pathogenic mechanisms by which hyperglycemia arises differ widely. American Diabetes Association categorized DM mainly as *types 1* and *2 diabetes* and the others \[[@B3]\]. Individuals with *type 1 diabetes* show extensive beta-cell destruction, and therefore no residual insulin secretion, requiring insulin for survival. Autoimmune *β*-cell destruction is the main cause of insulin deficiency in *type 1 diabetes* \[[@B4]\]. In some individuals with diabetes, adequate glycaemic control can be achieved with weight reduction, exercise, and/or oral agents. These individuals, that is, patients of *type 2 diabetes*, therefore, do not require insulin and may even revert to impaired glucose tolerance (IGT) or normoglycaemia \[[@B5]\]. It is mainly a heterogeneous disease with a complex pattern of inheritance. *Type 2 diabetes* is the commonest form of diabetes constituting about 90% of the total diabetic population, whereas *type 1 diabetes* constitutes about 10--15% of the diabetic population. Geographic, environmental, and genetic factors all play a major role in the variation of incidence of all types of diabetes. Although diabetes is classified into two major types---*type 1* (insulin dependent) and *type 2* (insulin independent) diabetes, there are some forms of diabetes which cannot be classified into either of these categories. One such less recognized and underdiagnosed manifestation of DM appears to affect adults with many characteristics of *type 2 diabetes* and carries a high risk of insulin dependency progression, the condition known as Latent Autoimmune Diabetes in Adults (LADA) \[[@B3]\]. The usual features of LADA patients reported are *onset of diabetes at ≥25 years of age, clinical presentation masquerading as nonobese type 2 diabetes, unlikely to have a family history of type 2 diabetes, initial control of hyperglycemia with diet and oral antidiabetic agents, evolution to insulin necessity within months, and some features of type 1 diabetes such as low fasting C-peptide and positive GAD auto antibodies*\[[@B6]--[@B8]\]. About 20% of the patients diagnosed with *type 2 diabetes* may have LADA. This accounts for *5--10% of the total diabetes population, the same number as type 1 diabetes* \[[@B9]\]. Despite the frequency of LADA, there are no universal recommendations regarding testing for islet antibodies in adult onset diabetes. A reliable clinical strategy is required to identify which adults with diabetes have a high likelihood of LADA and need testing for islet antibodies. Another important characteristic of LADA which faces controversy is the family history. Some reports suggest that LADA patients are unlikely to have family history of *type 2 diabetes*\[[@B10]\] while a recent study (Nord-Trøndelag Health Study) indicated strong evidence of family history as an important risk factor for LADA \[[@B11]\]. India is witnessing an epidemic of diabetes, more specifically *type 2 diabetes*. It has been observed that the onset of *type 2 diabetes* occurs at an early age in Asian population. Very less work has been done in context to LADA in the Indian population. Since it has been observed that the prevalence of diabetes in India and especially in Gujarat or Western population is significantly high, it follows that the prevalence of LADA in this population can be predicted to be high. Also, from the above reports, it is obvious that the differences between *type 1 diabetes* and LADA are not very well understood. Similarly, due to certain characteristics of LADA which phenotypically resemble *type 2 diabetes*, many LADA patients are often initially misdiagnosed as *type 2* diabetic patients. Since not much work has been done in the field of LADA in India, where diabetes affects a significant sector of the society, study of prevalence, characteristics and immunological markers of LADA, especially in the Western (Gujarat) population, where the prevalence of diabetes is high, would help in providing valuable insights into the underlying molecular and genetic mechanisms, similarities or differences with other types of diabetes and designing appropriate diagnostic criteria and treatment regimen for such patients.

2. Methods {#sec2}
==========

2.1. Epidemiological Study {#sec2.1}
--------------------------

The epidemiological study was carried out on 500 patients randomly selected, having any type of diabetes (excluding prediabetic syndrome or IGT) as per the Study Protocol approved by the Independent Ethics Committee Medilink Research Centre, Medilink Hospital, Ahmedabad, India.

### 2.1.1. Patient Recruitment and Screening {#sec2.1.1}

Patients attending DIACARE Clinic (Ahmedabad) and Medilink Hospital (Ahmedabad) confirmed as diabetic as per WHO criteria \[[@B12]\] were included in the epidemiological study. Patients not having diabetes or who are seriously ill were excluded from the study. All patients were given a patient information sheet and an informed consent form. Blood (10 mL) was collected for determination of various biochemical parameters.

### 2.1.2. Study Procedure {#sec2.1.2}

Various parameters evaluated for the epidemiological study were present age; age at onset of diabetes; duration of diabetes; gender; basal metabolic index (BMI); type of diabetes; family history of diabetes, if any; diet and lifestyle; medical complications; cholesterol levels; HbA1c levels; the current treatment regimen that the patient was following.

2.2. Estimation of C-Peptide Levels (*β*-Cell Function) and GAD Autoantibodies {#sec2.2}
------------------------------------------------------------------------------

### 2.2.1. Patient Recruitment {#sec2.2.1}

Eighty diabetic patients from the epidemiological study, attending DIACARE Clinic, and Medilink Hospital, Ahmedabad, were selected and recruited after checking the required inclusion and exclusion criteria. These patients were grouped into the four categories according to their type of diabetes: *type-1 diabetes* (*n* = 20); *type 2 diabetes* (*n* = 20); LADA suspects (*n* = 20); and patients newly diagnosed with diabetes and who could not been assigned a particular class of diabetes (*n* = 20).

Patients who were seriously ill or who had any specific objection for undergoing the tests for estimation of C-peptide and GAD auto antibodies were excluded from the study.

### 2.2.2. Determination of C-Peptide Levels {#sec2.2.2}

C-peptide levels were determined in the above groups using the EiAsy Way diagnostic kit (Diagnostic Biochem Canada Inc., Canada). The kit was used for the indirect quantitative determination of C-peptide by Enzyme Linked Immunosorbant Assay (ELISA) in human serum *in vitro*\[[@B13]\].

### 2.2.3. Estimation of GAD Autoantibodies {#sec2.2.3}

GAD autoantibodies were determined in the above-mentioned groups using Isletest GAD diagnostic kit (Biomerica, USA). The kit was used for an *in vitro* qualitative ELISA test for detection of circulating autoantibodies against GAD antigens \[[@B14]\].

2.3. Statistical Analysis {#sec2.3}
-------------------------

After recording the details of patients, the data was sorted into different groups according to the type of diabetes (*type 1, type 2*, LADA, and undiagnosed). The mean values were calculated for each parameter and compared in different groups. All results were expressed as mean ± SEM or as percentage. The statistical differences between various groups were evaluated by One Way Analysis of Variance (ANOVA) followed by Tukey\'s Test or Chi-Square Test with Yate\'s Correction (for nonparametric data). Data were considered significant at *P* \< 0.05 and highly significant at *P* \< 0.001. Statistical analysis was performed using GraphPad statistical software.

3. Results and Discussion {#sec3}
=========================

Results of different parameters evaluated amongst different classes of diabetic patients are summarized in [Table 1](#tab1){ref-type="table"}.

According to reports, *type 2 diabetes* constitutes a major section, that is, 80--90% of the total diabetic population \[[@B3]\]. Furthermore, about 20% of the patients diagnosed with LADA may have *type 2 diabetes*. This accounts for 5--10% of the total diabetes population, the same number as *type 1 diabetes* \[[@B9]\]. The results of the present study in a diabetic population revealed that the prevalence of *type 2 diabetes* was the highest (79.2%), followed by *type 1 diabetes* (6.2%) and LADA (5%) being nearly equal. This implies that the findings are in accordance with the reported data. Another group, comprising of patients who could not be categorized into one particular class of diabetes constituted of around 10% of the total diabetic population.

The prevalence of diabetes among males and females varies with geographical location, ethnicity, genetic and environmental factors ([Figure 1](#fig1){ref-type="fig"}).

According to the global prevalence of diabetes studies, overall, diabetes prevalence is higher in men than in women \[[@B15]\]. The results of the present study revealed that diabetes was found to be more prevalent in men (61%) than in women (39%). Thus the findings are in accordance with the reported data \[[@B15], [@B16]\]. Further studies on prevalence of different types of diabetes in males and females revealed that there was a significant difference in the prevalence pattern of diabetes in males and females in LADA and *type 1 diabetes* (*P* \< 0.01). *Type 1 diabetes* was found to be more prevalent in females (61.3%) than in males (38.7%), whereas the prevalence of LADA was significantly more in males (80%) than in females (20%). This suggests that males might be more prone towards development of LADA than females. There was a significant difference in prevalence pattern of *type 1* and *type 2 diabetes* (*P* \< 0.01). The prevalence pattern of *type 2 diabetes*, LADA, and undiagnosed patients was similar with no significant differences. Amongst *type 2 diabetes* patients, 62.12% were males and 37.87% were females. The similar prevalence pattern was seen in undiagnosed patients, that is, 54.16% males and 45.83% females suggesting that these patients are likely to be *type 2*or LADA.

Studies showed that the average age in different diabetic populations varied significantly. The average age of LADA (40.88 ± 1.48 years) patients was found to be significantly lower than *type 2 diabetes* and significantly higher than *type 1 diabetes* (*P* \< 0.01). The average age of patients of *type 1 diabetes* (21.64 ± 1.97 years) was found to be significantly lower than *type 2* and LADA (*P* \< 0.01). The average age of patients with *type 2* diabetes (55.69 ± 0.47 years) was the highest as compared to previous two groups. The average age in undiagnosed patients (44.46 ± 1.56 years) suggested that these patients are more likely to be patients with LADA than that with *type 2 diabetes*.

The average age at onset is a very critical factor in determining the type of diabetes as well as the treatment regimen to be decided for the patient. According to reported data, one of the important identifying characteristics of LADA is adult age at onset (\>25 years) \[[@B6]\]. The present studies showed that the average age at onset of diabetes in patients with LADA (33.4 ± 2.15 years) was significantly higher than patients with *type 1 diabetes* patients (12.55 ± 1.34 years) (*P* \< 0.001) and significantly lower than patients with *type 2 diabetes* (48.01 ± 0.50 years) (*P* \< 0.001). The mean age at onset in undiagnosed patients was observed to follow the same pattern (37.68 ± 1.28 years) strongly suggesting that these patients are more likely to be patients of LADA than *type 2 diabetes*. Results are presented in [Figure 2](#fig2){ref-type="fig"}.

Further studies regarding the prevalence of diabetes in different age groups revealed that *type 1 diabetes* was found to be most frequently occurring in the age group of 12--24 years in both males and females. Similarly *type 2 diabetes* was found to be most prevalent in males and females above 45 years of age. Interestingly LADA was found to occur most frequently in males of 36--45 years of age, while it was seen to affect most females above 45 years of age. This finding may lead to an assumption that LADA might be affecting females at a higher age than males.

The impact of family history of diabetes (FHD) on LADA is less well understood than those for *type 1* and *type 2 diabetes* \[[@B17]\]. Studies indicate that LADA has the same genetic features characteristic of *type 1 diabetes*, including an increased frequency of HLADQB1 genotypes \[[@B18], [@B19]\]. On the other hand, results from a British study indicated that 33% of patients with LADA have relatives with *type 2 diabetes* \[[@B20]\]. These findings suggest that LADA may share inherited features with both *type 1* and *type 2 diabetes* \[[@B11]\]. Results of family history in different types of diabetes revealed significant differences in the family history pattern of LADA and *type 1 diabetes* (*P* \< 0.05). While family history was absent in majority of patients with *type 1* (65.42%), *type 2* (57%), LADA (52%) as well as undiagnosed patients (70%) showed significant presence of family history. The pattern seen in undiagnosed patients was significantly different than in *type 1 diabetes* (*P* \< 0.01). There was a significant difference in family history patterns of *type 1*and *type 2 diabetes* (*P* \< 0.01). Absence of family history in patients with *type 1* suggests that *β*-cell destruction in *type 1 diabetes* might be due to viral infections or triggered autoimmune mechanisms. The noticeable presence of family history in *type 2 diabetes* is in accordance with the fact that *type 2 diabetes* is strongly hereditary in nature. Among LADA patients, a significant population (32%) showed paternal inheritance while a small proportion (8%) showed maternal inheritance, sibling inheritance (8%) and 4% showed both paternal and maternal inheritance. The results are shown in [Figure 3](#fig3){ref-type="fig"}.

Some reports suggest that LADA patients are unlikely to have a family history of *type 2 diabetes* \[[@B10]\], while some indicate presence of family history as an important risk factor for the development of LADA \[[@B11]\]. The interesting observation obtained in the present study would possibly open new doors for future exploration regarding pattern of inheritance in LADA patients.

In an effort to correlate BMI values with the type of diabetes, it was observed that a majority of patients with *type 1 diabetes* were healthy (58%) or underweight (38.6%) in nature suggesting possible alteration of carbohydrate, lipid, and protein metabolisms due to absolute insulin deficiency ([Figure 4](#fig4){ref-type="fig"}). The BMI values of patients with *type 1 diabetes* (19.96 ± 0.629) were significantly lower than patients with *type 2 diabetes* (27.95 ± 0.26) (*P* \< 0.001). BMI values of patients with *type 2 diabetes* showed that most of the patients of this category were overweight (47.3%). Significant proportions of these patients were found to be obese (22.9%) and very obese (2.27%). This implies that the findings are in agreement with the existing literature which states that obesity is one of the prime factors leading to development of *type 2 diabetes* and insulin resistance \[[@B21]\]. Furthermore, the BMI values of LADA patients (22 ± 0.55) were significantly lower than patients with *type 2 diabetes* (*P* \< 0.001) confirming the nonobese nature of these patients. None of the patients were obese which rules out the involvement of obesity and insulin resistance in development of LADA. Most of the patients (76%) displayed BMI values corresponding to healthy individuals suggesting that the gradual *β*-cell destruction in LADA is insufficient to cause significant weight loss. Reports suggest that BMI values are lower in LADA patients compared to patients with *type 2 diabetes*\[[@B22]\]. Thus our findings were in accordance with the reported data. The mean BMI levels in undiagnosed patients (25.68 ± 0.65) were significantly lower than patients with *type 2 diabetes* (*P* \< 0.05) and higher than patients with *type 1 diabetes* (*P* \< 0.001). A majority of the undiagnosed patients (55%) were found to be healthy, while a noticeable proportion (35%) was found to be overweight, though the proportion of overweight patients (35%) was relatively less in undiagnosed patients than that of *type 2* diabetics (47.3%) suggesting that these patients are likely to be patients of LADA.

Studies related to the treatment regimen for patients with different types of diabetes revealed that almost all (92.5%) patients with *type 1 diabetes* maintained optimum BSL with insulin. Majority of patients with *type 2 diabetes* (65.5%) were treated with oral hypoglycemic agents (OHA) while a noticeable proportion (29.5%) was on a combination of insulin and OHA suggesting development of progressive insulin dependence due to impairment in insulin secretion by various mechanisms \[[@B21], [@B23]\]. [Figure 5](#fig5){ref-type="fig"} depicts the results of statistical analysis on treatment regimen for different diabetic patients.

One of the major characteristics of LADA patients is initial response to OHA treatment \[[@B6]\]. Insulin dependency develops within a few years with gradual *β*-cell destruction necessitating a combined therapeutic regimen. In agreement with the reported literature, a major proportion of LADA patients (60%) were found to be taking a combination of insulin and OHA. The observation would help in designing an effective therapeutic regimen for LADA patients, that is, a combined treatment should be prescribed at the time of diagnosis of LADA to preserve the remaining *β*-cell mass though it is still unclear whether early treatment with insulin is beneficial for the remaining *β*-cells \[[@B9]\]. Additionally, an initial response to OHA with gradual insulin dependency observed in patients younger than the usual age occurrence of *type 2 diabetes* would be a strong identifying characteristic for LADA patients. Thus the type of treatment that patients comply to, the most, can be predictive in different types of diabetes, specifically, LADA. A majority of the undiagnosed patients (53.5%) were found to be on OHA, while a noticeable proportion (34.5%) was found to be on a combined treatment. The proportion of patients under combined treatment (34.5%) was relatively more than that of patients with *type 2 diabetes* (29.5%) on a combined treatment. The numbers of undiagnosed patients on OHA alone were less than that with *type 2 diabetes*, while the number of patients on insulin and OHA was more than that with *type 2 diabetes*. This strongly suggests that these are likely to be LADA patients who initially respond to OHA, but insulin dependency may occur within some time and the number of patients on a combined treatment may increase in near future.

Furthermore, a detailed study about the drug therapy distribution in different types of diabetic patients was performed and patients were evaluated for the type of therapy being given, that is, monodrug therapy or multidrug therapy. Almost all patients with *type 1 diabetes* (96.4%) showed optimum BSL with exclusive insulin monotherapy. No clear indication was observed for the remaining types of diabetes indicating that optimum BSL were maintained by a multidrug therapy (insulin + OHA or a combination of various OHA).

The HbA1c levels determination in diabetes gives an idea about the glycemic control during the last three months. Generally values above normal values (5--7%) indicate a poor glycemic control \[[@B24]\]. HbA1c levels determined in patients with different types of diabetes showed that LADA patients (10-11%) had significantly higher levels compared to *type 1* (9-10%) and *type 2 diabetes* (8--8.5%) (*P* \< 0.05). This was in agreement with the published data \[[@B23]\]. This shows poorer glycemic control in LADA patients compared to *type 1* and *type 2 diabetes*. Patients with*type 1 diabetes* showed relatively higher values as compared to patients with *type 2 diabetes*and lower than that of patients with LADA. Undiagnosed patients showed HbA1c values (7-8%) similar to patients with *type 2 diabetes.* The values were higher than normal HbA1c levels (5--7%) in all patients, indicating poor glycemic control in all patients \[[@B24]\].

Determination of serum cholesterol levels revealed that LADA patients (200--250 mg/dL) had significantly higher cholesterol levels than patients with *type 2 diabetes* (180--190 mg/dL), which was found to be in accordance with existing data \[[@B4]\]. This indicates that LADA patients are at a higher risk of developing cardiovascular complications than patients with *type 2 diabetes*. No data was available for patients with *type 1 diabetes*. Interestingly, undiagnosed patients also displayed cholesterol values greater than that of patients with *type 2 diabetes* suggesting possible categorization of these patients as LADA patients.

C-peptide is secreted at equimolar concentrations with insulin and is not degraded as rapidly as insulin. Hence determination of C-peptide is an advantageous test to quantify insulin and therefore to evaluate *β*-cell function. Since LADA is an autoimmune type of diabetes characterized by progressive *β*-cell destruction, estimation of C-peptide levels would prove to be an important measure to evaluate insulin secretion and *β*-cell function. The results of the C-peptide determination showed significantly low levels of C-peptide in LADA patients (0.34 ± 0.05 ng/mL) compared to patients with *type 2 diabetes* (1.26 ng/mL) (*P* \< 0.05). This is in accordance with existing data \[[@B6]\]. Many other studies suggested that LADA (also known as Ab positive *type 2 diabetes*) has lower C-peptide levels than patients with Ab negative *type 2 diabetes* \[[@B25]--[@B27]\]. Patients with *type 1 diabetes* also displayed lower C-peptide values (0.36 ± 0.05 ng/mL) as compared to patients with *type 2 diabetes*. Low C-peptide values in both the cases suggest insulin deficiency due to autoimmune *β*-cell destruction. Patients with *type 2 diabetes* displayed higher C-peptide values (1.26 ± 0.36 ng/mL) which show hyperinsulinemia due to compensatory increase in insulin secretion due to insulin resistance in *type 2 diabetes*. C-peptide values of undiagnosed patients were found to be higher than that of patients with *type 1* and LADA, but noticeably lower than that of patients with *type 2 diabetes* (0.63 ± 0.15 ng/mL) suggesting that insulin deficiency could progress with time and lower C-peptiode values may be achieved at a later stage. This indicates that these patients are likely to be patients of LADA. Results are presented in [Figure 6](#fig6){ref-type="fig"}.

The immunological evidence, common in both *type 1 diabetes* and LADA, is demonstrated by the presence of autoantibodies against islet cell antigens in the patients\' sera. Specifically, these antigens include 65 kDa glutamic acid decarboxylase (GAD65) and insulinoma-associated antigen (IA2). While *type 1 diabetes* shows both these autoantibodies, LADA typically demonstrates production of GAD65 autoantibodies \[[@B14]\]. Hence estimation of GAD autoantibodies can be used as an important diagnostic marker for diagnosis of LADA. Since the test was qualitative in nature, GAD autoantibodies levels above 0.95 units/mL indicated presence of GAD autoantibodies, while levels below this indicated absence of autoantibodies. Results of GAD autoantibodies determination revealed marked presence of GAD autoantibodies predominantly in LADA patients (0.95 ± 0.06 units/mL) as compared to patients with *type 2 diabetes* (*P* \< 0.05) ([Figure 7](#fig7){ref-type="fig"}).

GAD autoantibodies were significantly present in undiagnosed patients (1.01 ± 0.07 units/mL) as compared to patients with *type 2 diabetes* (0.7 ± 0.06 units/mL) and *type 1 diabetes* (0.76 ± 0.05 units/mL). This strongly depicts autoimmune nature of the disease, especially LADA, which is significantly in accordance with the existing data \[[@B6]\]. The characteristic presence of these antibodies in undiagnosed patients further strengthens the fact that these patients are most likely to be patients of LADA. The absence of GAD autoantibodies in *type 2 diabetes* implicates nonautoimmune nature of the disease \[[@B28], [@B29]\]. The absence of these autoantibodies in *type 1 diabetes* do not imply that the disease is nonautoimmune in nature, but merely suggests that other autoantibodies like ICA, IA2, or tyrosine phosphatase autoantibodies may be involved \[[@B30], [@B31]\].

4. Conclusions {#sec4}
==============

LADA patients comprise an important section of the diabetic population, its prevalence being nearly equal as that of *type 1 diabetes*. It can be characterized predominantly by adult age at onset (30--40 years), nonobese body type, and initial response to OHA gradually leading to insulin dependency, characteristically low C-peptide levels, and marked presence of GAD autoantibodies. Thus determination of C-peptide levels and GAD autoantibodies is strongly recommended for confirmatory diagnosis of LADA. The characteristic presence of GAD autoantibodies in LADA implies that further studies that identify possible role of GAD autoantibodies in LADA may help in understanding the pathogenesis of the disease. Interestingly the study showed that LADA seems to affect males more than females. LADA patients have also shown significant presence of family history, further exploration of which would provide newer insights into the role of family history as an important risk factor in development of LADA. Furthermore, genotyping of LADA patients will prove to be substantial in understanding the role of various genes involved in the disease. In conclusion, it appears that, while some anthropologic characteristics can be useful for the preliminary screening of LADA patients in a diabetic population, C-peptide levels and GAD autoantibodies determination can be considered as confirmatory diagnostic markers for LADA. Appropriate diagnosis of LADA would prevent misdiagnosis as *type 2 diabetes* and would help in optimum treatment of LADA patients so that residual *β*-cell function is preserved and the further autoimmune destruction of *β*-cells is delayed. For further information, see Supplementary Material available online at doi:10.5402/2012/580202.

Supplementary Material {#supplementary-material-sec}
======================

###### 

ANNEXURE--I includes the Patient\'s Record Form; ANNEXURE--II contains the Patient Information Sheet; ANNEXURE--III presents the Patient Informed Consent Form; ANNEXURE--IV is the Statement of Approval of Ethical Committee; ANNEXURE--V is the Patient Information Sheet; ANNEXURE--VI is the Patient Informed Consent Form.

###### 

Click here for additional data file.
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![Mean C-peptide levels in different types of diabetes. Black circle: significantly lower C-peptide levels in *type 1 diabetes* as compared to *type 2 diabetes* (*P* \< 0.05). Black square: significantly higher C-peptide levels in *type 2 diabetes* as compared to *type 1 diabetes* and LADA (*P* \< 0.05). Black triangle: significantly lower C-peptide levels in LADA as compared to *type 2 diabetes* (*P* \< 0.05).](ISRN.PHARMACOLOGY2012-580202.006){#fig6}
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###### 

Comparative evaluation of different parameters in different types of diabetes including LADA.

  Parameter                                 Type 1              Type 2          LADA             Undiagnosed                         
  ----------------------------------------- ------------------- --------------- ---------------- ---------------- ---- ---- -------- -------
  Prevalence (%)                            6.2                 79.2            5                9.6                                 
                                                                                                                                     
  Gender-wise prevalence                                                                                                             
   Males (%)                                38.7                62.12           80               54.16                               
   Females (%)                              61.3                37.87           20               45.83                               
                                                                                                                                     
  Average age (yrs)                         21.64 ± 1.97        55.69 ± 0.47    40.8 ± 1.48      44.46 ± 1.56                        
  Range (yrs)                               6--59               33--82          23--55           25--65                              
                                                                                                                                     
  Mean age at onset of diabetes (yrs)       12.55 ± 1.34        48.01 ± 0.5     33.4 ± 2.15      37.68 ± 1.28                        
  Range (yrs)                               2--30               30--75          22--44           20--45                              
                                                                                                                                     
  Prevalence in different age groups (%)    M                   F               M                F                M    F    M        F
   \<12 years                               16.66               10.52           0                0                0    0    0        0
   12--24 years                             41.66               63.15           0                0                5    0    0        0
   25--35 years                             16.66               26.31           0.8              0.8              15   20   11.5     36.36
   36--45 years                             16.66               0               15.04            15.04            60   20   30.76    22.72
   \>45 years                               8.33                0               54.14            84.14            20   60    57.69   40.90
                                                                                                                                     
  Family history (% patients)                                                                                                        
   Present                                  35.48               57.07           52               70.81                               
   Absent                                   65.42               42.93           48               29.17                               
                                                                                                                                     
  Basal metabolic index (BMI, % patients)                                                                                            
   Underweight (U)                          38.6                1.76            12               5                                   
   Healthy (H)                              58                  25.5            76               55                                  
   Overweight (H)                           3.2                 47.3            12               35                                  
   Obese (O)                                0                   22.9            0                5                                   
   Very obese (VOb)                         0                   2.27            0                0                                   
                                                                                                                                     
  Mean BMI                                  19.96 ± 0.629       27.95 ± 0.26    22 ± 0.55        25.68 ± 0.65                        
  BMI range                                 13.75--25           16--45          15--26           16.5--34                            
                                                                                                                                     
  Treatment regimen (% patients)                                                                                                     
   Insulin                                  92.5                3.5             20               12                                  
   OHA                                      3.5                 65.5            16               53.5                                
   Insulin + OHA                            3.5                 29.5            60               34.5                                
                                                                                                                                     
  Drug therapy (% patients)                                                                                                          
   1 DT                                     96.4                18              23.6             28                                  
   2 DT                                     3.6                 28              23.8             28                                  
   3 DT                                     0                   29              23.8             12.5                                
   4 DT                                     0                   21.5            28.5             22                                  
   5 DT                                     0                   3               0                9.4                                 
                                                                                                                                     
  Mean HbA1c levels (%)                     9.661 ± 1.10        8.21 ± 0.25     10.45 ± 0.75     7.89 ± 0.47                         
                                                                                                                                     
  Mean cholesterol levels (mg/dL)           No data available   181.96 ± 5.28   222.33 ± 26.87   210.90 ± 13.59                      
                                                                                                                                     
  Mean C-peptide levels (ng/mL)             0.36 ± 0.05         1.26 ± 0.36     0.34 ± 0.05      0.63 ± 0.15                         
                                                                                                                                     
  GAD autoantibodies                        0.76 ± 0.05         0.7 ± 0.06      0.95 ± 0.06      1.01 ± 0.07                         
  (units/mL)                                Absent              Absent          Present          Present                             
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